Peptides / Sexual health and hormones

Synthetic analog · 9 amino acids · 1,209.4 Da

Leuprolide

ApprovedBanned in sport

Leuprolide (Lupron, Eligard), also called leuprorelin, is a GnRH agonist approved in the US and EU countries, including for advanced prostate cancer, and banned in sport. Studies in people tested it on sex hormones, tumor growth, pain and bone, and tracked side effects. PepBank shows 631 results on leuprolide from 112 studies in people, and 76 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Eligard, Leuprolide acetate, Leuprorelin, Lupron

9 amino acids, from first to lastEHWSYLLRP

Evidence level: Large trials in people631 of 707 results come from studies in people, including randomized trials.

Results in people

631

89% of 707 results

Results in animals

10% of 707 results

Results in lab cells

under 1% of 707 results

From computer models

0% of 707 results

Overview

Leuprolide at a glance

What it is	Synthetic analog, 9 amino acids
Approval	Approved in the US and EU (Leuprolide acetate for depot suspension, 2018)
In sport	Banned in sport (WADA S2.2.1)
Studies	131 studies with results. 130 of them gave leuprolide, with 707 results. 631 in people71 in animals5 in lab cells
Best study in people	Randomized controlled trial with 1,071 people (2019)
Clinical trials	393 registered: 85 active or planned, 149 with posted results
Community use	Patients with advanced prostate cancer using the Cipla-labelled leuprolide acetate depot suspension for three-month administration.

The science

What is leuprolide?

Leuprolide, also called leuprorelin, is a nine-residue GnRH agonist analog.

Amino acids in one chain

The history of leuprolide

1982
The oldest paper on leuprolide in PepBank is from 1982.
1994October
A registered trial of leuprolide started (NCT00002597).
2018August
FDA approved Leuprolide acetate for depot suspension for selected three-month depot formulation for advanced prostate cancer.

Leuprolide structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 9 amino acidsFrom the first amino acid to the last

−E1HWSY5LL+RP

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Leuprolide is a synthetic analog of 9 amino acids, with no ring, 2 changed amino acids.

Formula

C₅₉H₈₄N₁₆O₁₂

Molecular weight

1,209.4 g/mol

CAS number

53714-56-0

Target

Gonadotropin-releasing hormone receptor (gene GNRHR): agonistEvidence: Official prescribing information, mechanism of action

Development

Highest phase: past the trial stage (see status).

Identifiers

PubChem 657181, ChEMBL CHEMBL1201199, UNII EFY6W0M8TG, DrugBank DB00007

Full sequence, SMILES and InChIKey

Three-letter sequence
pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt

InChIKey
GFIJNRVAKGFPGQ-LIJARHBVSA-N

SMILES
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6

See charge, composition and 3D structure on the Scientific page

The evidence

What leuprolide studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people631 of 707 results come from studies in people, including randomized trials.

Sex hormones and fertility

197 results · 166 in people · 30 animal · 1 lab

In men with advanced prostate cancer, sustained testosterone suppression was less frequent with leuprolide than relugolix. The New England journal of medicine, 2020

Top results

In men with advanced prostate cancer, sustained testosterone suppression was less frequent with leuprolide than relugolix. (The New England journal of medicine, 2020)
In women with fibroids, leuprolide controlled bleeding in 89% versus 90% with ulipristal 5 mg. (The New England journal of medicine, 2012)
In advanced prostate cancer, higher peak leuprorelin levels with the 3-month depot did not alter testosterone rises versus the 1-month depot. (Urologia internationalis, 1998)

Cancer

75 results · 73 in people · 2 animal

In men with prostate cancer, time to PSA progression was similar with intermittent and continuous leuprorelin. European urology, 2016

Top results

In men with prostate cancer, time to PSA progression was similar with intermittent and continuous leuprorelin. (European urology, 2016)
In women with uterine myomas, leuprorelin reduced myoma diameter more than lynestrenol. (European journal of obstetrics, gynecology, and reproductive biology, 2000)
In patients with advanced prostate cancer, 81% of evaluable patients had no progression with depot leuprolide. (The Journal of urology, 1990)

Sexual and women's health

58 results · 55 in people · 3 animal

In women with fibroids, uterine volume decreased from 505 to 305 cu cm after 12 weeks of leuprolide. Fertility and sterility, 1989

Top results

In women with fibroids, uterine volume decreased from 505 to 305 cu cm after 12 weeks of leuprolide. (Fertility and sterility, 1989)
Loss of sexual interest was more common with leuprolide than with bicalutamide in men with prostate cancer. (Journal of clinical oncology, 2004)
In women with fibroids, substantial uterine shrinkage was more common with leuprolide than placebo. (Obstetrics and gynecology, 1991)

Pain

35 results · 35 in people

In women with endometriosis-associated pain, pain score changed by -10.6 mm with leuprorelin versus -6.2 mm with relugolix 10 mg. Fertility and sterility, 2021

Top results

In women with endometriosis-associated pain, pain score changed by -10.6 mm with leuprorelin versus -6.2 mm with relugolix 10 mg. (Fertility and sterility, 2021)
In women with functional bowel disease, leuprolide 7.5 mg improved abdominal pain versus placebo. (Digestive diseases and sciences, 1998)
In men with prostate cancer, bone pain and urinary symptoms improved in 80% with either leuprolide or diethylstilbestrol. (Urology, 1985)

Bones and joints

25 results · 25 in people

In men with prostate cancer, longer leuprorelin treatment did not increase vertebral fractures compared with shorter treatment. BJU international, 2014

Top results

In men with prostate cancer, longer leuprorelin treatment did not increase vertebral fractures compared with shorter treatment. (BJU international, 2014)
In women with fibroids, bone density loss was similar with leuprorelin and relugolix. (Obstetrics and gynecology, 2019)
Women with endometriosis lost more bone density with leuprolide than with DMPA-SC at month 6. (Fertility and sterility, 2006)

Blood and clotting

19 results · 19 in people

In women undergoing fibroid surgery, red blood cell counts after surgery were higher with leuprolide pretreatment than direct surgery. American journal of obstetrics and gynecology, 1998

Top results

In women undergoing fibroid surgery, red blood cell counts after surgery were higher with leuprolide pretreatment than direct surgery. (American journal of obstetrics and gynecology, 1998)
Blood parameters improved after leuprolide treatment in women with uterine fibroids. (Journal of the Society for Gynecologic Investigation, 2005)
Anemia response was higher with leuprolide 7.5 mg plus iron than placebo plus iron. (Obstetrics and gynecology, 1995)

Leuprolide has 1,829 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

All 131 leuprolide studies by area Open the Scientific page

Key leuprolide studies

Studies in people come first, then studies in animals and in the lab.

People
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial
Denham et al. 2019 · The Lancet. Oncology · 1,071 people · cited by 85
2 results
People
Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer
Denham et al. 2014 · BJU international · 1,071 people · cited by 23
3 results
People
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Shore et al. 2020 · The New England journal of medicine · 930 people · cited by 346
4 results
People
Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND)
Schulman et al. 2016 · European urology · 701 people · cited by 37
8 results
People
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial
Denham et al. 2014 · The Lancet. Oncology · 536 people · cited by 88
10 results

All 131 Leuprolide studies

Leuprolide clinical trials

ClinicalTrials.gov lists 393 trials of leuprolide. 85 are active or planned, and 149 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

Phase 3completed3,246 people

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Phase 3completed2,028 people

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Phase 3active, not recruiting1,939 planned

All 162 Leuprolide trials

Status and safety

Is leuprolide approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S2.2.1.

Yes. Approved in the US and EU (Leuprolide acetate for depot suspension, 2018). The FDA label for Leuprolide acetate for depot suspension says: “Selected three-month depot formulation for advanced prostate cancer” Banned in sport (WADA S2.2.1).

Laws and labels change, so check the regulator for the current status.

Leuprolide side effects and safety

PepBank has 167 safety results from studies of leuprolide. 167 of them come from studies in people.

Safety results from studies (167)

In men with prostate cancer, longer leuprorelin treatment did not increase vertebral fractures compared with shorter treatment. (BJU international, 2014)
In women with endometriosis, metrorrhagia was among adverse events reported at similar frequency with leuprorelin and relugolix 40 mg. (BMC women's health, 2021)
In men with prostate cancer, persistent rectal dysfunction did not differ between treatment arms, including shorter and longer leuprorelin treatment. (Radiotherapy and oncology, 2012)
In men with prostate cancer, deaths numbered 175 with longer leuprorelin treatment and 200 with shorter treatment. (The Lancet. Oncology, 2019)
In men with advanced prostate cancer, major cardiovascular events were more frequent with leuprolide than relugolix. (The New England journal of medicine, 2020)
In men with prostate cancer, adverse event counts were similar with intermittent and continuous leuprorelin. (European urology, 2016)
In men with prostate cancer, overall mortality did not differ between longer and shorter leuprorelin treatment. (The Lancet. Oncology, 2014)
In women with fibroids, adverse events were similar with leuprorelin and relugolix. (Obstetrics and gynecology, 2019)
Women with endometriosis lost more bone density with leuprolide than with DMPA-SC at month 6. (Fertility and sterility, 2006)
In women with endometriosis, similarly small numbers stopped leuprolide or danazol because of side effects. (American journal of obstetrics and gynecology, 1993)
In men with prostate cancer, overall adverse event occurrence was similar with leuprolide and abarelix. (Urology, 2001)
In patients with metastatic prostate cancer, painful breast enlargement was less frequent with leuprolide than DES. (The New England journal of medicine, 1984)
In spinal and bulbar muscular atrophy, drug-related adverse events did not differ significantly between leuprorelin and placebo. (The Lancet. Neurology, 2010)
In patients with advanced prostate cancer, hot flashes were more common with leuprolide than with diethylstilbestrol. (Urology, 1986)
In men with prostate cancer, adverse events were generally similar between leuprolide and relugolix groups. (European urology oncology, 2024)
In women with endometriosis, hot flush frequency with leuprorelin was comparable with relugolix 40 mg. (Fertility and sterility, 2021)
Ovarian hyperstimulation syndrome rates were similar with leuprolide and the antagonist in women with PCOD. (The Journal of reproductive medicine, 2005)
In women with suspected endometriosis, no participants stopped leuprolide or placebo because of adverse events. (Obstetrics and gynecology, 1999)
In patients with leiomyomas or endometriosis, bleeding was less frequent with leuprolide than buserelin at 8 weeks. (The journal of obstetrics and gynaecology research, 2000)
In patients with endometriosis, leuprolide caused more vasodilatation than placebo. (Fertility and sterility, 1990)
Men with prostate cancer lost lumbar spine bone density with leuprolide, while density increased with bicalutamide. (Journal of clinical oncology, 2004)
In men with prostate cancer, depression did not differ significantly between leuprolide and bicalutamide. (Psycho-oncology, 2008)
Leuprolide reduced testicular volume compared with placebo. (The Journal of urology, 1994)
In breast cancer patients, side effects did not differ between monthly and three-monthly leuprolide. (Cancer chemotherapy and pharmacology, 1999)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
22·5 mg every 3 months	Human	human	intramuscular	18 months	Randomized trial in people · n = 1,071	Denham 2019
22.5 mg 3-month depot	Human	human	Not reported	36 months	Randomized trial in people · n = 701	Schulman 2016
22·5 mg every 3 months	Human	human	intramuscular	18 months	Randomized trial in people · n = 536	Denham 2014
7.5 mg every 28 days	Human	human	intramuscular	Not reported	Randomized trial in people · n = 284	Heyns 2003
1.88 mg or 3.75 mg monthly	Human	human	injection	24 weeks	Randomized trial in people · n = 281	Osuga 2019
7.5 mg	Human	human	intramuscular	Not reported	Randomized trial in people · n = 269	McLeod 2001
11.25 mg every three months	Human	human	subcutaneous	Planned treatment: 2 years	Randomized trial in people · n = 227	Schmid 2002
3.75 mg monthly	Human	human	subcutaneous injection	12 weeks	Randomized trial in people · n = 183	Osuga 2021
11.25 mg or 22.5 mg	Human	human	injection every 12 weeks	48 weeks	Randomized trial in people · n = 109	Bowen 2015
3.75 mg per month	Human	human	subcutaneous	6 months	Randomized trial in people · n = 48	Regidor 2001
3.75 mg monthly	Human	human	subcutaneous	16 weeks	Randomized trial in people · n = 46	Verspyck 2000
7.5 mg monthly	Human	human	intramuscular	12 months	Randomized trial in people	Klotz 2008
3.75 mg once monthly	Human	human	intramuscular	3 months	Randomized trial in people	Donnez 2012
3.75 mg every 4 weeks	Human	human	intramuscular depot injection	24 weeks	Randomized trial in people	Strowitzki 2010
11.25 mg every 12 weeks	Human	human	subcutaneous	48 weeks	Randomized trial in people	Katsuno 2010
3.75 or 1.88 mg every 4 weeks	Human	human	subcutaneous	24 weeks	Randomized trial in people	Harada 2022
3.75 mg every 4 weeks	Human	human	subcutaneous	24 weeks	Randomized trial in people	Osuga 2021
22.5 mg every 12 weeks	Human	human	Not reported	Not reported	Randomized trial in people · n = 713	2023
7.5 mg/mo	Human	human	Not reported	1 year	Randomized trial in people	Tombal 2010
Every-3-month depot	Human	human	Not reported	Not reported	Randomized trial in people · n = 599	Schmid 2007
11.25 mg every 3 months	Human	human	intramuscular	6 months	Randomized trial in people · n = 274	Schlaff 2006
3.75 mg monthly	Human	human	injection	Not reported	Randomized trial in people · n = 270	Wheeler 1993
7.5 mg or 3.75 mg	Human	human	Not reported	12 weeks	Randomized trial in people · n = 265	Stovall 1995
1 mg daily	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 199	1984
1 mg/day	Human	human	Not reported	Not reported	Randomized trial in people · n = 199	Garnick 1986
0.5 mg single dose	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 164	Isik 2009
3.75 mg every 4 weeks	Human	human	intramuscular	24 weeks	Randomized trial in people · n = 128	Friedman 1991
3.75 mg/mo	Human	human	Not reported	3 months	Randomized trial in people · n = 100	Ling 1999
3.75 mg monthly	Human	human	intramuscular	3 months	Randomized trial in people · n = 89	Busacca 2001
11.25 mg every 3 months	Human	human	intramuscular	6 months	Randomized trial in people · n = 84	Lee 2012
3.75 mg every 4 weeks	Human	human	subcutaneous or intramuscular	Not reported	Randomized trial in people · n = 78	du 2002
7.5 mg monthly or 22.5 mg every 3 months	Human	human	Not reported	Not reported	Randomized trial in people · n = 71	Sharifi 2002
Two depot injections 28 days apart	Human	human	injection	Not reported	Randomized trial in people · n = 67	Zullo 1998
1.88 mg every 28 days	Human	human	Not reported	Not reported	Randomized trial in people · n = 67	Takeuchi 2000
3.75 mg	Human	human	Not reported	Not reported	Randomized trial in people · n = 52	Dlugi 1990
3.75 mg every 28 days	Human	human	injection	24 weeks	Randomized trial in people · n = 50	Eri 1994
3.75 mg every month or 11.25 mg every 3 months	Human	human	Not reported	until disease recurrence or progression, or a maximum of 24 months	Randomized trial in people · n = 50	Boccardo 1999
11.25 mg every 3 months	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 42	Tunn 1998
1.88 mg every 4 weeks	Human	human	subcutaneous	24 weeks	Randomized trial in people · n = 41	Watanabe 1992
7.5 mg	Human	human	injection	49 days	Randomized trial in people · n = 32	Santosa 2017

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The selected US prescription label describes a leuprolide acetate depot formulation for advanced prostate cancer. The regimen below applies to that formulation.

Reported routines and cautions

What people use it for

Patients with advanced prostate cancer using the Cipla-labelled leuprolide acetate depot suspension for three-month administration.S1

Reported regimens

Regimens that community sources report for Leuprolide. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Patients with advanced prostate cancer using the Cipla-labelled leuprolide acetate depot suspension for three-month administration.Official label dosing of an approved product	intramuscular injectionThe label requires physician supervision.	22.5 mg per dose	every 12 weeks	Not stated	Single official US label source.	S1

Cautions

The label warns about tumor flare, metabolic changes, cardiovascular disease, QT prolongation, convulsions, and fetal harm. It contraindicates use with known hypersensitivity to GnRH agonists or formulation excipients.S1
The label requires testosterone monitoring and monitoring for metabolic and cardiovascular changes. Patients with vertebral metastases or urinary tract obstruction need close observation during initial therapy.S1
Safety and effectiveness in pediatric patients have not been established for this selected formulation. Safety and efficacy in females have not been established.S1
The later FDA label warns about severe cutaneous adverse reactions. It requires treatment interruption for suspected reactions and permanent discontinuation if confirmed.S3

Status notes

The agency source records nationally authorised products. This does not establish a central authorisation or current availability in every country.S2

Community sources

S1Cipla leuprolide acetate depot US prescribing information (opens in a new tab)dailymed.nlm.nih.gov
S2EMA regulatory information (opens in a new tab)ema.europa.eu
S3FDA label for NDA 205054, November 2024 (opens in a new tab)accessdata.fda.gov

Gaps

This record covers one selected label regimen. It does not document a separate community-use regimen. Other formulations and patient groups require their own labels.

Questions and more

Ask a question about leuprolide

The answer links to every study it uses.

What does the evidence say about leuprolide?Is leuprolide tested in people?Compare with Oxytocin Compare with Triptorelin (Trelstar, Decapeptyl)

Sources

Database: PepBank data for leuprolide (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about leuprolide

Leuprolide

ApprovedBanned in sport

Also known as Eligard, Leuprolide acetate, Leuprorelin, Lupron

What it is

Synthetic analog, 9 amino acids

Approval

Approved in the US and EU (Leuprolide acetate for depot suspension, 2018)

In sport

Banned in sport (WADA S2.2.1)

Studies

131 studies with results. 130 of them gave leuprolide, with 707 results.
631 in people71 in animals5 in lab cells

Best study in people

Randomized controlled trial with 1,071 people (2019)

Clinical trials

393 registered: 85 active or planned, 149 with posted results

Community use

Patients with advanced prostate cancer using the Cipla-labelled leuprolide acetate depot suspension for three-month administration.

Dose as reported

Class

Species

Route

Duration

Design

Source

22·5 mg every 3 months

Human

human

intramuscular

18 months

Randomized trial in people · n = 1,071

Denham 2019

22.5 mg 3-month depot

Human

human

Not reported

36 months

Randomized trial in people · n = 701

Schulman 2016

22·5 mg every 3 months

Human

human

intramuscular

18 months

Randomized trial in people · n = 536

Denham 2014

7.5 mg every 28 days

Human

human

intramuscular

Not reported

Randomized trial in people · n = 284

Heyns 2003

1.88 mg or 3.75 mg monthly

Human

human

injection

24 weeks

Randomized trial in people · n = 281

Osuga 2019

7.5 mg

Human

human

intramuscular

Not reported

Randomized trial in people · n = 269

McLeod 2001

11.25 mg every three months

Human

human

subcutaneous

Planned treatment: 2 years

Randomized trial in people · n = 227

Schmid 2002

3.75 mg monthly

Human

human

subcutaneous injection

12 weeks

Randomized trial in people · n = 183

Osuga 2021

11.25 mg or 22.5 mg

Human

human

injection every 12 weeks

48 weeks

Randomized trial in people · n = 109

Bowen 2015

3.75 mg per month

Human

human

subcutaneous

6 months

Randomized trial in people · n = 48

Regidor 2001

3.75 mg monthly

Human

human

subcutaneous

16 weeks

Randomized trial in people · n = 46

Verspyck 2000

7.5 mg monthly

Human

human

intramuscular

12 months

Randomized trial in people

Klotz 2008

3.75 mg once monthly

Human

human

intramuscular

3 months

Randomized trial in people

Donnez 2012

3.75 mg every 4 weeks

Human

human

intramuscular depot injection

24 weeks

Randomized trial in people

Strowitzki 2010

11.25 mg every 12 weeks

Human

human

subcutaneous

48 weeks

Randomized trial in people

Katsuno 2010

3.75 or 1.88 mg every 4 weeks

Human

human

subcutaneous

24 weeks

Randomized trial in people

Harada 2022

3.75 mg every 4 weeks

Human

human

subcutaneous

24 weeks

Randomized trial in people

Osuga 2021

22.5 mg every 12 weeks

Human

human

Not reported

Randomized trial in people · n = 713

2023

7.5 mg/mo

Human

human

Not reported

1 year

Randomized trial in people

Tombal 2010

Every-3-month depot

Human

human

Not reported

Randomized trial in people · n = 599

Schmid 2007

11.25 mg every 3 months

Human

human

intramuscular

6 months

Randomized trial in people · n = 274

Schlaff 2006

3.75 mg monthly

Human

human

injection

Not reported

Randomized trial in people · n = 270

Wheeler 1993

7.5 mg or 3.75 mg

Human

human

Not reported

12 weeks

Randomized trial in people · n = 265

Stovall 1995

1 mg daily

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 199

1984

1 mg/day

Human

human

Not reported

Randomized trial in people · n = 199

Garnick 1986

0.5 mg single dose

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 164

Isik 2009

3.75 mg every 4 weeks

Human

human

intramuscular

24 weeks

Randomized trial in people · n = 128

Friedman 1991

3.75 mg/mo

Human

human

Not reported

3 months

Randomized trial in people · n = 100

Ling 1999

3.75 mg monthly

Human

human

intramuscular

3 months

Randomized trial in people · n = 89

Busacca 2001

11.25 mg every 3 months

Human

human

intramuscular

6 months

Randomized trial in people · n = 84

Lee 2012

3.75 mg every 4 weeks

Human

human

subcutaneous or intramuscular

Not reported

Randomized trial in people · n = 78

du 2002

7.5 mg monthly or 22.5 mg every 3 months

Human

human

Not reported

Randomized trial in people · n = 71

Sharifi 2002

Two depot injections 28 days apart

Human

human

injection

Not reported

Randomized trial in people · n = 67

Zullo 1998

1.88 mg every 28 days

Human

human

Not reported

Randomized trial in people · n = 67

Takeuchi 2000

3.75 mg

Human

human

Not reported

Randomized trial in people · n = 52

Dlugi 1990

3.75 mg every 28 days

Human

human

injection

24 weeks

Randomized trial in people · n = 50

Eri 1994

3.75 mg every month or 11.25 mg every 3 months

Human

human

Not reported

until disease recurrence or progression, or a maximum of 24 months

Randomized trial in people · n = 50

Boccardo 1999

11.25 mg every 3 months

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 42

Tunn 1998

1.88 mg every 4 weeks

Human

human

subcutaneous

24 weeks

Randomized trial in people · n = 41

Watanabe 1992

7.5 mg

Human

human

injection

49 days

Randomized trial in people · n = 32

Santosa 2017

Context

Route

Amount

How often

How long

Agreement

Sources

Patients with advanced prostate cancer using the Cipla-labelled leuprolide acetate depot suspension for three-month administration.Official label dosing of an approved product

intramuscular injectionThe label requires physician supervision.

22.5 mg per dose

every 12 weeks

Not stated

Single official US label source.

Leuprolide

Leuprolide at a glance

What is leuprolide?

The history of leuprolide

Leuprolide structure and chemistry

What leuprolide studies show

Sex hormones and fertility

Cancer

Sexual and women's health

Pain

Bones and joints

Blood and clotting

Key leuprolide studies

Leuprolide clinical trials

Is leuprolide approved?

Leuprolide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about leuprolide

Related peptides

Sources

Leuprolide

Leuprolide at a glance

What is leuprolide?

The history of leuprolide

Leuprolide structure and chemistry

What leuprolide studies show

Sex hormones and fertility

Cancer

Sexual and women's health

Pain

Bones and joints

Blood and clotting

Key leuprolide studies

Leuprolide clinical trials

Is leuprolide approved?

Leuprolide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about leuprolide

Related peptides

Sources